Il ruolo della chemioterapia nei trattamenti combinati delle metastasi cerebrali e dei gliomi

Translated title of the contribution: Combined therapeutic approaches for primary and secondary brain tumors: The role of chemotherapy

M. G. Passarin, E. Bazzoli, E. Anghileri, C. Ghimenton, A. M. Musso, G. Moretto

Research output: Contribution to journalArticle

Abstract

The term "brain tumor" includes a variety of neoplasms growing within the central nervous system. They can be roughly distinguished into primary brain tumors and secondary tumors (metastases), originated from a primary tumor located outside the brain. The treatment options for brain tumors differ according to the subtypes. Brain tumors constitute a disease that is systemic to the brain; for this reason surgical resection, although effective for palliation and prolonged survival, is never curative. Radiation therapy is the most effective non surgical therapy for astrocytomas. Until recently, the use of chemotherapy in addition to cranial irradiation was more controversial. Typically chemotherapeutic agents, such as carmustine, procarbazine, lomustine and vincristine have been currently use. Approximately 5 years ago temozolomide was approved for the treatment of recurrent anaplastic astrocytoma and glioblastoma. Temozolomide is an orally active alkylating agent, with manageable side effects, that has demonstrated its efficacy against recurrent glioblastoma. More recently, a large randomised clinical trial showed a significant survival benefit for temozolomide in combination with radiotherapy compared with radiation alone. In particular, for newly diagnosed glioblastoma, combined daily radiotherapy with daily temozolomide followed by six cycles of adjuvant temozolamide improves overall survival. This benefit is especially observed in patients with a methylated promotor of the MGMT gene which encodes an alkyltransferase. Whereas primary brain cancer is a devastating but fortunately relatively rare disease, brain metastases occur much more frequently. It has been estimated that 20-50% of patients suffering from breast, lung or skin (melanoma) neoplasms will develop brain metastases. Whereas whole-brain radiotherapy is commonly applied, the efficacy of chemotherapy for the treatment of brain metastases is still undefined. Yet, there is now a growing consensus that systemic chemotherapy may be useful. Patients with brain metastases are a heterogeneous group and require individualized therapy. The approach to a patient with brain metastases should be based on the number of brain metastases, the extent of extracranial disease and performance status of the patient.

Original languageItalian
Pages (from-to)165-169
Number of pages5
JournalRivista Medica
Volume13
Issue number1
Publication statusPublished - Mar 2007

Fingerprint

temozolomide
Brain Neoplasms
Drug Therapy
Brain
Neoplasm Metastasis
Radiotherapy
Glioblastoma
Therapeutics
Astrocytoma
Survival
Alkyl and Aryl Transferases
Lomustine
Procarbazine
Cranial Irradiation
Carmustine
Neoplasms
Alkylating Agents
Vincristine
Skin Neoplasms
Rare Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Passarin, M. G., Bazzoli, E., Anghileri, E., Ghimenton, C., Musso, A. M., & Moretto, G. (2007). Il ruolo della chemioterapia nei trattamenti combinati delle metastasi cerebrali e dei gliomi. Rivista Medica, 13(1), 165-169.

Il ruolo della chemioterapia nei trattamenti combinati delle metastasi cerebrali e dei gliomi. / Passarin, M. G.; Bazzoli, E.; Anghileri, E.; Ghimenton, C.; Musso, A. M.; Moretto, G.

In: Rivista Medica, Vol. 13, No. 1, 03.2007, p. 165-169.

Research output: Contribution to journalArticle

Passarin, MG, Bazzoli, E, Anghileri, E, Ghimenton, C, Musso, AM & Moretto, G 2007, 'Il ruolo della chemioterapia nei trattamenti combinati delle metastasi cerebrali e dei gliomi', Rivista Medica, vol. 13, no. 1, pp. 165-169.
Passarin MG, Bazzoli E, Anghileri E, Ghimenton C, Musso AM, Moretto G. Il ruolo della chemioterapia nei trattamenti combinati delle metastasi cerebrali e dei gliomi. Rivista Medica. 2007 Mar;13(1):165-169.
Passarin, M. G. ; Bazzoli, E. ; Anghileri, E. ; Ghimenton, C. ; Musso, A. M. ; Moretto, G. / Il ruolo della chemioterapia nei trattamenti combinati delle metastasi cerebrali e dei gliomi. In: Rivista Medica. 2007 ; Vol. 13, No. 1. pp. 165-169.
@article{cad336eb039643de83c880db1e6fda84,
title = "Il ruolo della chemioterapia nei trattamenti combinati delle metastasi cerebrali e dei gliomi",
abstract = "The term {"}brain tumor{"} includes a variety of neoplasms growing within the central nervous system. They can be roughly distinguished into primary brain tumors and secondary tumors (metastases), originated from a primary tumor located outside the brain. The treatment options for brain tumors differ according to the subtypes. Brain tumors constitute a disease that is systemic to the brain; for this reason surgical resection, although effective for palliation and prolonged survival, is never curative. Radiation therapy is the most effective non surgical therapy for astrocytomas. Until recently, the use of chemotherapy in addition to cranial irradiation was more controversial. Typically chemotherapeutic agents, such as carmustine, procarbazine, lomustine and vincristine have been currently use. Approximately 5 years ago temozolomide was approved for the treatment of recurrent anaplastic astrocytoma and glioblastoma. Temozolomide is an orally active alkylating agent, with manageable side effects, that has demonstrated its efficacy against recurrent glioblastoma. More recently, a large randomised clinical trial showed a significant survival benefit for temozolomide in combination with radiotherapy compared with radiation alone. In particular, for newly diagnosed glioblastoma, combined daily radiotherapy with daily temozolomide followed by six cycles of adjuvant temozolamide improves overall survival. This benefit is especially observed in patients with a methylated promotor of the MGMT gene which encodes an alkyltransferase. Whereas primary brain cancer is a devastating but fortunately relatively rare disease, brain metastases occur much more frequently. It has been estimated that 20-50{\%} of patients suffering from breast, lung or skin (melanoma) neoplasms will develop brain metastases. Whereas whole-brain radiotherapy is commonly applied, the efficacy of chemotherapy for the treatment of brain metastases is still undefined. Yet, there is now a growing consensus that systemic chemotherapy may be useful. Patients with brain metastases are a heterogeneous group and require individualized therapy. The approach to a patient with brain metastases should be based on the number of brain metastases, the extent of extracranial disease and performance status of the patient.",
keywords = "Brain tumor, Chemotherapy, Metastases",
author = "Passarin, {M. G.} and E. Bazzoli and E. Anghileri and C. Ghimenton and Musso, {A. M.} and G. Moretto",
year = "2007",
month = "3",
language = "Italian",
volume = "13",
pages = "165--169",
journal = "Rivista Medica",
issn = "1127-6339",
publisher = "New Magazine Edizioni S.r.l.",
number = "1",

}

TY - JOUR

T1 - Il ruolo della chemioterapia nei trattamenti combinati delle metastasi cerebrali e dei gliomi

AU - Passarin, M. G.

AU - Bazzoli, E.

AU - Anghileri, E.

AU - Ghimenton, C.

AU - Musso, A. M.

AU - Moretto, G.

PY - 2007/3

Y1 - 2007/3

N2 - The term "brain tumor" includes a variety of neoplasms growing within the central nervous system. They can be roughly distinguished into primary brain tumors and secondary tumors (metastases), originated from a primary tumor located outside the brain. The treatment options for brain tumors differ according to the subtypes. Brain tumors constitute a disease that is systemic to the brain; for this reason surgical resection, although effective for palliation and prolonged survival, is never curative. Radiation therapy is the most effective non surgical therapy for astrocytomas. Until recently, the use of chemotherapy in addition to cranial irradiation was more controversial. Typically chemotherapeutic agents, such as carmustine, procarbazine, lomustine and vincristine have been currently use. Approximately 5 years ago temozolomide was approved for the treatment of recurrent anaplastic astrocytoma and glioblastoma. Temozolomide is an orally active alkylating agent, with manageable side effects, that has demonstrated its efficacy against recurrent glioblastoma. More recently, a large randomised clinical trial showed a significant survival benefit for temozolomide in combination with radiotherapy compared with radiation alone. In particular, for newly diagnosed glioblastoma, combined daily radiotherapy with daily temozolomide followed by six cycles of adjuvant temozolamide improves overall survival. This benefit is especially observed in patients with a methylated promotor of the MGMT gene which encodes an alkyltransferase. Whereas primary brain cancer is a devastating but fortunately relatively rare disease, brain metastases occur much more frequently. It has been estimated that 20-50% of patients suffering from breast, lung or skin (melanoma) neoplasms will develop brain metastases. Whereas whole-brain radiotherapy is commonly applied, the efficacy of chemotherapy for the treatment of brain metastases is still undefined. Yet, there is now a growing consensus that systemic chemotherapy may be useful. Patients with brain metastases are a heterogeneous group and require individualized therapy. The approach to a patient with brain metastases should be based on the number of brain metastases, the extent of extracranial disease and performance status of the patient.

AB - The term "brain tumor" includes a variety of neoplasms growing within the central nervous system. They can be roughly distinguished into primary brain tumors and secondary tumors (metastases), originated from a primary tumor located outside the brain. The treatment options for brain tumors differ according to the subtypes. Brain tumors constitute a disease that is systemic to the brain; for this reason surgical resection, although effective for palliation and prolonged survival, is never curative. Radiation therapy is the most effective non surgical therapy for astrocytomas. Until recently, the use of chemotherapy in addition to cranial irradiation was more controversial. Typically chemotherapeutic agents, such as carmustine, procarbazine, lomustine and vincristine have been currently use. Approximately 5 years ago temozolomide was approved for the treatment of recurrent anaplastic astrocytoma and glioblastoma. Temozolomide is an orally active alkylating agent, with manageable side effects, that has demonstrated its efficacy against recurrent glioblastoma. More recently, a large randomised clinical trial showed a significant survival benefit for temozolomide in combination with radiotherapy compared with radiation alone. In particular, for newly diagnosed glioblastoma, combined daily radiotherapy with daily temozolomide followed by six cycles of adjuvant temozolamide improves overall survival. This benefit is especially observed in patients with a methylated promotor of the MGMT gene which encodes an alkyltransferase. Whereas primary brain cancer is a devastating but fortunately relatively rare disease, brain metastases occur much more frequently. It has been estimated that 20-50% of patients suffering from breast, lung or skin (melanoma) neoplasms will develop brain metastases. Whereas whole-brain radiotherapy is commonly applied, the efficacy of chemotherapy for the treatment of brain metastases is still undefined. Yet, there is now a growing consensus that systemic chemotherapy may be useful. Patients with brain metastases are a heterogeneous group and require individualized therapy. The approach to a patient with brain metastases should be based on the number of brain metastases, the extent of extracranial disease and performance status of the patient.

KW - Brain tumor

KW - Chemotherapy

KW - Metastases

UR - http://www.scopus.com/inward/record.url?scp=34248222712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248222712&partnerID=8YFLogxK

M3 - Articolo

VL - 13

SP - 165

EP - 169

JO - Rivista Medica

JF - Rivista Medica

SN - 1127-6339

IS - 1

ER -